Patient no. | Age/Sex | Underlying disease | Status at transplantation | Conditioning | Stem cell source | GVHD prophylaxis | Prophylactic antibiotics |
1 | 49/male | ATLL | CR1 | TBI (12 Gy) + CY | UR-BM | Tacrolimus + sMTX | LVFX |
2 | 44/male | AML | CR1 | Flu + BU + TBI (2 Gy) | UR-BM | Tacrolimus + sMTX | - |
3 | 20/male | ALL | CR1 | TBI (12 Gy) + CY | Rel-PB | Ciclosporin + sMTX | TFLX |
4 | 45/female | ALL | CR2 | TBI (12 Gy) + CA + CY | UR-CB | Tacrolimus + sMTX | LVFX |
5 | 44/male | LBL | PR1 | TBI (12 Gy) + CA + CY | UR-CB | Tacrolimus + sMTX | LVFX |
6 | 44/male | MDS | CR1 | TBI (12 Gy) + CA + CY | UR-CB | Tacrolimus + sMTX | LVFX |
7 | 62/male | ALL | CR2 | Flu + Mel + TBI (4 Gy) | UR-CB | Tacrolimus + sMTX | LVFX |
8 | 24/male | AML | CR2 | TBI (12 Gy) + CY | UR-BM | Tacrolimus + sMTX | LVFX |
9 | 46/male | ATLL | CR1 | TBI (12 Gy) + CY | Rel-PB | Ciclosporin + sMTX | CPFX |
10 | 19/male | ALCL | primary refractory | TBI (12 Gy) + CY | UR-BM | Tacrolimus + sMTX | LVFX |